CXADR and primary cutaneous T-cell non-Hodgkin lymphoma: Moreover, all hCAR-Vβ2 T cell versions (Supplementary Fig. 4a) showed very limited pre-existing immunoreactivity to IgM in the sera of various healthy donors (Supplementary Fig. 4b) and CTCL patients (Supplementary Fig. 4c).